[Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
Zidek
Walter
W
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D002309:Cardiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000191:economics; D003928:Diabetic Nephropathies / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005060:Europe; D005194:Family Practice; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D013997:Time Factors; D014481:United States
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers